Strategies targeting FLT3 beyond the kinase inhibitors

Acute myeloid leukemia (AML) is a hematological malignancy characterized by clonal expansion and differentiation arrest of the myeloid progenitor cells, which leads to the accumulation of immature cells called blasts in the bone marrow and peripheral blood. Mutations in the receptor tyrosine kinase...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Pharmacology & therapeutics (Oxford) 2021-09, Vol.225, p.107844-107844, Article 107844
Hauptverfasser:	Almatani, Mohammed F., Ali, Atham, Onyemaechi, Sandra, Zhao, Yang, Gutierrez, Lucas, Vaikari, Vijaya Pooja, Alachkar, Houda
Format:	Artikel
Sprache:	eng
Schlagworte:	AML CAR-T FLT3 FLT3-ITD fms-Like Tyrosine Kinase 3 - drug effects fms-Like Tyrosine Kinase 3 - genetics Humans Leukemia, Myeloid, Acute - drug therapy microRNAs Monoclonal antibody Mutation - drug effects Protein Kinase Inhibitors - pharmacology Receptor Protein-Tyrosine Kinases - genetics scFv
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!